Avelumab in First-line NSCLC (JAVELIN Lung 100)

• Status: Active, not recruiting
• Trial end date: 2025-06-09

Summary

The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors

• Phase: Phase 3

Details

• Lead Sponsor: EMD Serono Research & Development Institute, Inc.
• Collaborators: Merck KGaA; Merck KGaA, Darmstadt, Germany
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Avelumab; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed